TG Therapeutics, Inc.
TGTXTG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of hematologic cancers and autoimmune diseases. The company’s portfolio includes agents aimed at addressing unmet medical needs in multiple sclerosis, B-cell malignancies, and other related conditions. Based in the United States, TG Therapeutics is engaged in both research and development efforts to bring innovative treatments to patients.
Company News
U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trad...
TG Therapeutics' CEO Michael S. Weiss will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit on November 12, 2025, discussing the company's developments in B-cell disease treatments.
TG Therapeutics reported strong Q2 2025 results with BRIUMVI sales growth, raising full-year revenue guidance to $585 million. The company is focusing on expanding product reach, developing new dosing regimens, and exploring additional indications for its multiple sclerosis therapy.
TG Therapeutics reported strong Q1 2025 financial results for its multiple sclerosis drug BRIUMVI, with $119.7 million in U.S. net sales and raised its full-year revenue guidance. The company also provided updates on its pipeline, including plans to advance subcutaneous BRIUMVI and a new therapy for progressive MS.
Several mid-cap stocks, including Bilibili, MARA Holdings, and ZEEKR Intelligent Technology, saw significant gains last week. The article highlights the top 8 mid-cap gainers and discusses the reasons behind their performance.
